Xiaodong He

Xiaodong He


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
XHXiaodong He
Xiaodong He
NYNan Yao
Nan Yao
WLWen Jia Liang
Wen Jia Liang
YZYou Cheng Zhang
You Cheng Zhang
BACKGROUND: The high recurrence rate of hepatocellular carcinoma (HCC) after potentially curative treatment determines the long-term prognosis.OBJECTIVE: To evaluate the efficacy and safety of adjuvant therapies in patients with HCC who have undergone hepatic resection, transplantation or locoregional ablation therapy.METHODS: Several databases were searched to identify randomized controlled trials (RCTs) fulfilling the predefined selection criteria. Meta-analyses were performed to estimate the effects of adjuvant therapies of any modality on recurrence-free survival (RFS) and overall survival (OS).RESULTS: Eight adjuvant modalities were identified from 27 eligible RCTs conducted predominantly in Asian populations comparing adjuvant with no adjuvant therapy. Adjuvant chemotherapy, internal radiation and heparanase inhibitor PI-88 therapy failed to improve RFS or OS, while interferon (IFN) therapy yielded significant survival results. The findings of adjuvant vitamin analogue therapy required further examination. Adjuvant adoptive immunotherapy conferred significant benefit for RFS but not for OS. Although cancer vaccine therapy and radioimmunotherapy may improve survival after radical surgery, the results were from single, small-scale trials. Severe side effects were observed in the studies of adjuvant chemotherapy and of IFN therapy.CONCLUSIONS: Adjuvant IFN therapy can improve both RFS and OS; however, the benefits of using this agent should be weighed against its side effects. Combination of systemic and transhepatic arterial chemotherapy is not recommended for HCC after potentially curative treatment. Other adjuvant therapies produce limited success for survival. Additional RCTs with proper design are required to establish the role of adjuvant therapies for HCC.

9 September 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
XHXiaodong He
Xiaodong He
ZGZhi-Hui Guo
Zhi-Hui Guo
JTJin-Hui Tian
Jin-Hui Tian
KYKe-Hu Yang
Ke-Hu Yang
XXXiao-Dong Xie
Xiao-Dong Xie

1 February 2009 in The American Journal of Surgery
Verified
Journal Article
Closed access
SYSun Hu Yang
Sun Hu Yang
YZYou Cheng Zhang
You Cheng Zhang
KYKe Hu Yang
Ke Hu Yang
YLYou Ping Li
You Ping Li
XHXiaodong He
Xiaodong He
NSNeel Sharma
Neel Sharma

14 July 2009 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SSShaoliang Sun
Shaoliang Sun
KYKehu Yang
Kehu Yang
MGMingtai Gao
Mingtai Gao
XHXiaodong He
Xiaodong He
JTJinhui Tian
Jinhui Tian
BMBin Ma
Bin Ma

19 December 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
XLXiaohong Liu
Xiaohong Liu
KSKai Sun
Kai Sun
HCHao Chen
Hao Chen
ASAilin Song
Ailin Song
XZXiaoyun Zhang
Xiaoyun Zhang
XHXiaodong He
Xiaodong He
This study was aimed to investigate whether ATP-sensitive potassium channel (KATP) is involved in curcumin’s anti-proliferative effects against gastric cancer. In an in vitro study, gastric cancer cell line SGC-7901 was treated with curcumin at serial concentrations and co-administrated with the KATP opener, diazoxide. The effect of curcumin and diazoxide on proliferation were assessed by MTT assay. Mitochondrial membrane potential (MMP) was studied by flow cytometry detection of rhodamine 123 staining. Apoptosis was evaluated by flow cytometry detection of Annexin V propidium iodide double staining. In an in vivo study, SGC-7901 cells were planted into nude mice as xenografts. Animals were treated with curcumin co-administered with diazoxide. Tumor volume and tumor weight were observed. Curcumin incubation significantly induced loss of MMP in SGC-7901 cells in a dose- dependent manner (P < 0.05); the cell apoptotic rate also dramatically increased after curcumin incubation in a dose-dependent manner (P < 0.05). After co-administration with diazoxide, however, we found that both the MMP-loss-inducing and the apoptosis-inducing effects of curcumin in SGC-7901 cells were significantly impaired (all P < 0.05). As a result, the proliferation of SGC-7901 cells was maintained by diazoxide treatment. Impaired mitoKATP opening causes MMP loss, and is involved in curcumin-induced apoptosis in gastric cancer.

17 July 2008 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
SSShaoliang Sun
Shaoliang Sun
KYKehu Yang
Kehu Yang
XHXiaodong He
Xiaodong He
JTJinhui Tian
Jinhui Tian
BMBin Ma
Bin Ma
LJLei Jiang
Lei Jiang